Limitations in the design of the experiment of Boulware et al[1] are considered in Cohen[2]. They are not subject to correction but they are reported for readers' consideration. However, they made an analysis for the incidence based on Fisher's hypothesis test for means while they published detailed time dependent data which were not analyzed  . Here we make an original analyses with this time dependent data adopting a more informative regression analysis. We conclude their randomized, double-blind, placebo-controlled trial present consistent statistical evidence, at 99\% confidence level, that the treatment of Covid-19 patients with hydroxychloroquine is effective in reducing the appearance of symptoms if used from 0 to 2 days after exposure to virus with estimated relative reduction in symptomatic outcomes of 72\% after 0 days, 48.9\% after 1 day and 29.3\% after 2 days. For 3 days after exposure, the estimated relative reduction is 15.7\% but results are not statistically conclusive and for 4 or more days after exposure there is no statistical evidence that hydroxychloroquine is effective in reducing the appearance of symptoms. Our results show that the time elapsed between infection and the beginning of treatment is crucial for the efficacy of hydroxychloroquine as a treatment to Covid-19.
Limitations in the design of the experiment of Boulware et al[1] are considered in Cohen[2]. They are not subject to correction but they are reported for readers' consideration. However, they made an analysis for the incidence based on Fisher's hypothesis test for means while they published detailed time dependent data which were not analyzed , disregarding an important information . Here we make the analyses with this time dependent data adopting a simple regression analysis. We conclude their randomized, double-blind, placebo-controlled trial presents statistical evidence, at 99\% confidence level, that the treatment of Covid-19 patients with hydroxychloroquine is effective in reducing the appearance of symptoms if used before or right after exposure to the virus. For 0 to 2 days after exposure to virus , the estimated relative reduction in symptomatic outcomes is 72\% after 0 days, 48.9\% after 1 day and 29.3\% after 2 days. For 3 days after exposure, the estimated relative reduction is 15.7\% but results are not statistically conclusive and for 4 or more days after exposure there is no statistical evidence that hydroxychloroquine is effective in reducing the appearance of symptoms. Our results show that the time elapsed between infection and the beginning of treatment is crucial for the efficacy of hydroxychloroquine as a treatment to Covid-19.
A
, disregarding an important information
R
an original
the
R
more informative
simple
R
present consistent
presents
R
from
before or right after exposure to the virus. For
R
with
, the
R
of
is